Galenica Reports Steady Sales Growth Amid Market Challenges

Galenica AG announced a 7.3% sales growth to CHF 1,409.7 million in the first four months of 2026, driven by strong performances in pharmacy and wholesale. The company's diversified approach helped mitigate a seasonal drop in cold and pain relief products. The "Products & Care" segment rose by 11.6%, with notable contributions from the Pharmacies Omni-Channel and the digital expansion of sales channels.

Growth in the home care and diagnostics sectors further bolstered results. The newly acquired "Diagnostics" segment added CHF 40.8 million to sales, while the "Logistics & IT" segment saw a 4.3% increase, thanks to the wholesale business. Despite a downturn in over-the-counter product sales, Galenica maintains a positive outlook with expected growth between 5% and 7% for the year.